Back to top
more

Protalix BioTherapeutics (PLX)

(Delayed Data from AMEX)

$1.14 USD

1.14
231,575

-0.02 (-1.72%)

Updated May 3, 2024 04:00 PM ET

After-Market: $1.17 +0.03 (2.63%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Protalix BioTherapeutics, Inc. [PLX]

Reports for Purchase

Showing records 41 - 60 ( 77 total )

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 41

04/17/2017

Company Report

Pages: 5

AIR DNase Demonstrates Potential; Raising Price Target

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 42

11/29/2016

Company Report

Pages: 5

Fabry Competitor Falters; Potentially Higher Brazil Sales; Raising Price Target to $4 per Share

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 43

11/29/2016

Company Report

Pages: 5

Fabry Competitor Falters; Potentially Higher Brazil Sales; Raising Price Target to $4 per Share

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 44

10/25/2016

Company Report

Pages: 5

PRX-102 Phase 3 Fabry Disease Trial Patient Dosing Begins; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 45

10/25/2016

Company Report

Pages: 5

PRX-102 Phase 3 Fabry Disease Trial Patient Dosing Begins; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 46

08/18/2016

Company Report

Pages: 4

2Q16 Financial Results Reported; Clinical Catalysts Ahead; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 47

08/18/2016

Company Report

Pages: 4

2Q16 Financial Results Reported; Clinical Catalysts Ahead; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 48

07/11/2016

Company Report

Pages: 5

Protalix Enters Phase 2 in Cystic Fibrosis; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 49

07/11/2016

Company Report

Pages: 5

Protalix Enters Phase 2 in Cystic Fibrosis; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 50

05/17/2016

Industry Report

Pages: 48

Unearthing Gems in the Promised Land: An Overview of the Israeli Life Sciences Sector

Provider: H.C. Wainwright & Co., Inc.

Price: 100.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 51

04/04/2016

Company Report

Pages: 24

We are initiating coverage with a Buy rating and a 12- month price target of $3.50 per share.

Provider: Rodman & Renshaw, Co.

Price: 75.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 52

04/04/2016

Company Report

Pages: 24

We are initiating coverage with a Buy rating and a 12- month price target of $3.50 per share.

Provider: H.C. Wainwright & Co., Inc.

Price: 75.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 53

08/22/2012

Industry Report

Pages: 9

Similar to Last Year, Enterprise & Client Solid State Drives Remain Primary Focus at the 2012 Flash Memory Summit; Increasing SanDisk PT to $39

Provider: WEDBUSH SECURITIES INC.

Analyst: VAN HEES B

Price: 25.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 54

06/07/2012

Daily Note

Pages: 5

Termination of Coverage

Provider: AURIGA USA

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 55

05/10/2012

Company Report

Pages: 5

Reiterate Buy and $9 PT; Q1 Uneventful; Eyes on Elelyso launch in US

Provider: AURIGA USA

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 56

05/04/2012

Company Report

Pages: 8

Upgrade to Buy and raise PT to $9.00; Elelyso Approval Validates the Technology Platform

Provider: AURIGA USA

Analyst: YANG D

Price: 25.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 57

04/30/2012

Company Report

Pages: 5

Downgrade to Hold and Maintain $8 PT; Uncomfortable betting on May 1 PDUFA Binary Event

Provider: AURIGA USA

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 58

03/01/2012

Company Report

Pages: 5

No Material Changes in 10-K Filing; Reiterate BUY and $8 PT

Provider: AURIGA USA

Analyst: YANG D

Price: 10.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 59

11/29/2011

Company Report

Pages: 15

Initiate on a Biotech Company with Innovative Manufacturing Process; BUY, $8 PT

Provider: AURIGA USA

Analyst: YANG D

Price: 50.00

Research Provided by a Third Party

Company: Protalix BioTherapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 60

09/06/2011

Daily Note

Pages: 3

Dropping Coverage of Biotechnology Stocks

Provider: CAPSTONE INVESTMENTS

Price: 10.00

Research Provided by a Third Party